Augmentation of venlafaxine with bupropion: Risks associated with a triple monoamine reuptake inhibition approach to partially responsive depression

Journal of Clinical Psychiatry

Volumn 74, Issue 2, 2013, Pages

  Andrade, Chittaranjan ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; TRIPLE REUPTAKE INHIBITOR; VENLAFAXINE;

ADULT; AGITATION; ANXIETY; ARTICLE; BLOOD PRESSURE; CASE REPORT; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RESTLESSNESS; SIDE EFFECT; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84874597746     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13f08348     Document Type: Article

References (21)

1. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000;57(5):503-509. doi:10.101/archpsyc.57.5.503 PubMed (Pubitemid 30257265)
2. Stahl SM, Pradko JF, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159-166. doi:10.408/PC.v06n0403 PubMed
3. Erfurth A, Michael N, Stadtland C, et al. Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients. Neuropsychobiology. 2002;45(suppl 1):33-36. doi:10.159/049259 PubMed (Pubitemid 34224976)
4. Paslakis G, Gilles M, Deuschle M. Clinically relevant pharmacokinetic interaction between venlafaxine and bupropion: a case series. J Clin Psychopharmacol. 2010;30(4):473-474. doi:10.1097/JCP.0b013e3181e5c0e4 PubMed
5. Kotlyar M, Brauer LH, Tracy TS, et al. Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol. 2005;25(3):226-229. doi:10.1097/01.jcp. 0162805.46453.e3 PubMed (Pubitemid 40685785)
6. Nichols AI, Focht K, Jiang Q, et al. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig. 2011;31(3):155-167. doi:10.2165/158630-0-0 PubMed
7. Lourenco MT, Kennedy SH. Desvenlafaxine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2009;5:127-136. PubMed
8. Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry. 2002;63(3):181-186. doi:10.408/JCP.v63n0302 PubMed (Pubitemid 34407075)
9. Launiainen T, Rasanen I, Vuori E, et al. Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int J Legal Med. 2011;125(3):349-358. doi:10.107/s0414-010-0461-5 PubMed
10. Zhou S-F, Liu J-P, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89-295. doi:10.1080/03602530902843483 PubMed
11. Preskorn S, Patroneva A, Silman H, et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol. 2009;29(1):39-43. doi:10.1097/JCP.0b013e318192e4c1 PubMed
12. Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos. 2008;36(12):2484-2491. doi:10.124/dmd.108.021527 PubMed
13. Nichols AI, Fatato P, Shenouda M, et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol. 2009;49(2):219-228. doi:10.17/0912708326716 PubMed
14. Oganesian A, Shilling AD, Young-Sciame R, et al. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. Psychopharmacol Bull. 2009;42(2):47-63. PubMed
15. Faucette SR, Hawke RL, Lecluyse EL, et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos. 2000;28(10):1222-1230. PubMed
16. Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther. 2005;27(11):1685-1695. doi:10.1016/j.clinthera.205.1.01 PubMed (Pubitemid 41815222)
17. Faucette SR, Hawke RL, Shord SS, et al. Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab Dispos. 2001;29(8):1123-1129. PubMed (Pubitemid 32660531)
18. O'Donnell CJ, Grime K, Courtney P, et al. The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery setting. Drug Metab Dispos. 2007;35(3):381-385. doi:10.124/dmd.106.01234 PubMed (Pubitemid 46333900)
19. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry. 1989;50(7):256-261. PubMed (Pubitemid 19193449)
20. Lopes Rocha F, Fuzikawa C, Riera R, et al. Antidepressant combination for major depression in incomplete responders: a systematic review. J Affect Disord. 2013;144(1-2):1-6. doi:10.1016/j.jad.2012.04.048 PubMed
21. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1):43-64. doi:10.2165/1587620-0-0 PubMed